Atul Ltd 2018-19

( ` cr) Particulars Life Science Chemicals Performance and Other Chemicals Others Total 2018-19 2017-18 2018-19 2017-18 2018-19 2017-18 2018-19 2017-18 ¡ƑūǛƥ ċĚljūƑĚ ƥîǊ ǬǮǦȦǩǪ ǪǧǨȦǨǧ iii) Other information Segment assets 856.52 723.78 1,708.02 1,591.20 60.16 73.59 ǨȡǬǨǪȦǭǦ 2,388.57 ÀŠîŕŕūČîƥĚē ČūŞŞūŠ îƙƙĚƥƙ 919.27 625.02 Total assets ǩȡǫǪǩȦǯǭ 3,013.59 Segment liabilities ǧǯǭȦǧǪ ǧǪǯȦǨǧ ǩǬǪȦǮǭ 395.50 9.50 18.98 571.51 563.69 ÀŠîŕŕūČîƥĚē ČūŞŞūŠ liabilities ǨǪǨȦǯǫ 185.97 Total liabilities ǮǧǪȦǪǬ ǭǪǯȦǬǬ Additions to assets and intangible assets 81.05 ǪǦȦǮǯ 153.83 ǯǬȦǪǩ ǯȦǮǪ ǧȦǨǪ ǨǪǪȦǭǨ 138.56 ÀŠîŕŕūČîƥĚē îēēĿƥĿūŠƙ ƥū assets and intangible assets 0.68 2.31 ¹ūƥîŕ ČîƎĿƥîŕ ĚǊƎĚŠēĿƥƭƑĚȜ ǨǪǫȦǪǦ ǧǪǦȦǮǭ Depreciation ǩǨȦǪǫ 31.29 ǮǧȦǭǪ 73.93 1.68 2.38 115.87 107.60 ÀŠîŕŕūČîƥĚē ēĚƎƑĚČĿîƥĿūŠ ǩȦǦǪ 2.78 Total depreciation 118.91 110. 38 c) Secondary segment - geographical ( ` cr) Particulars In India Outside India Total 2018-19 2017-18 2018-19 2017-18 2018-19 2017-18 Segment revenue 1,978.13 1,630.60 2,059.68 1,707.32 ǪȡǦǩǭȦǮǧ 3,337.92 Carrying cost of assets by location of assets 3,225.26 ǨȡǭǪǮȦǭǪ 318.71 ǨǬǪȦǮǫ ǩȡǫǪǩȦǯǭ 3,013.59 Additions to assets and intangible assets* ǨǪǫȦǪǦ ǧǪǦȦǮǭ - - ǨǪǫȦǪǦ ǧǪǦȦǮǭ Other disclosures: Ŀȴ ¹ĺĚ HƑūƭƎ ĺîƙ ēĿƙČŕūƙĚē ċƭƙĿŠĚƙƙ ƙĚijŞĚŠƥ îƙ ƥĺĚ ƎƑĿŞîƑǋ ƙĚijŞĚŠƥ ǅĺĿČĺ ĺîǄĚ ċĚĚŠ ĿēĚŠƥĿǛĚē ĿŠ ŕĿŠĚ ǅĿƥĺ ƥĺĚ TŠē ¬ ǧǦǮ ‘Operating Segments’ taking into account the organisation structure as well as the differing risks and returns. ĿĿȴ ¹ĺĚ ƙĚijŞĚŠƥ ƑĚǄĚŠƭĚȡ ƑĚƙƭŕƥƙȡ îƙƙĚƥƙ îŠē ŕĿîċĿŕĿƥĿĚƙ ĿŠČŕƭēĚ ƑĚƙƎĚČƥĿǄĚ îŞūƭŠƥƙ ĿēĚŠƥĿǛîċŕĚ ƥū ĚîČĺ ƙĚijŞĚŠƥ îŠē îŞūƭŠƥƙ allocated on a reasonable basis. iii) The Group accounts for inter segment sales and transfers at market price. *Including capital work-in-progress and capital advances Note 29.16 Business combination a) Brief of the transaction During the year, a subsidiary company acquired manufacturing facilities of Polydrug Laboratories Pvt Ltd based at Ambernath additional MIDC through slump sale as a continuing business effective, January 01, 2019. The transaction has been entered by a subsidiary company to move ahead in value chain from Active Pharmaceutical Ingredient (API) Intermediates manufacturer to an API manufacturer. Note 29.15 Segment information (continued) ǨǪǨ Atul Ltd | Annual Report 2018-19 Corporate Overview 01-22 Statutory Reports 23-105 Financial Statements 107-250